Recent studies in cultured human fibroblasts have led to the identification of a cell surface receptor that binds serum low density lipoproteins (LDL) and thereby regulates cellular cholesterol metabolism (1-3). Binding of LDL to this receptor produces four known secondary metabolic events: i, the cholesterol of LDL is transferred into the cell (4); ii, the cellular mechanism for esterification of cholesterol is stimulated (5); iii, the activity of hydroxymethylglutaryl-CoA reductase (NADPH) [mevalonate: NADP+ oxidoreductase (CoA-acylating) EC 1.1.1.34], the rate-controlling enzyme in cholesterol biosynthesis, is suppressed (6, 7); and iv, the protein component of LDL is degraded to its constituent amino acids (2, 3). These actions of the LDL receptor can be studied either by direct measurement of 125I-labeled LDL binding to fibroblasts (1-3) or by assays of the effect of LDL on any one of the four secondary metabolic events (2-7).
neither suppress hydroxymethylglutaryl-CoA reductase (NADPH) [mevalonate: NADP+ oxidoreductase (CoA-acylating) EC 1.1.1.34] activity nor stimulate cellular cholesterol esterification, even'when examined in the presence of concentrations of lipoprotein 500 times higher than those required to produce maximal biologic effects in normal cells. The second type of mutation, described herein, results in a receptor that has a reduced but not absent function.' Fibroblasts from three-subjects who possess this mutation, i.e., receptor-defective homozygotes, show partial suppression of the same enzyme activity and a detectable increase in cholesterol esterification capacity in the presence of high levels of low density lipoproteins. It was calculated that their degree of function could be achieved if they possessed only about 10% of the normal binding of low density lipoprotein. This level of binding was too low to be reliably detected by the "2I-labeled low density lipoprotein binding assay. The finding of a second class of mutant cells in which a defect in low density lipoprotein binding is associated with simultaneous defects in both suppression of hydroxymethylglutaryl-CoA reductase activity and stimulation of cholesterol ester formation provides further 'evidence for the coordinate control of these two processes by the low density lipoprotein receptor.
Recent studies in cultured human fibroblasts have led to the identification of a cell surface receptor that binds serum low density lipoproteins (LDL) and thereby regulates cellular cholesterol metabolism (1) (2) (3) . Binding of LDL to this receptor produces four known secondary metabolic events: i, the cholesterol of LDL is transferred into the cell (4); ii, the cellular mechanism for esterification of cholesterol is stimulated (5); iii, the activity of hydroxymethylglutaryl-CoA reductase (NADPH) [mevalonate: NADP+ oxidoreductase (CoA-acylating) EC 1.1.1.34], the rate-controlling enzyme in cholesterol biosynthesis, is suppressed (6, 7) ; and iv, the protein component of LDL is degraded to its constituent amino acids (2, 3) . These actions of the LDL receptor can be studied either by direct measurement of 125I-labeled LDL binding to fibroblasts (1) (2) (3) or by assays of the effect of LDL on any one of the four secondary metabolic events (2) (3) (4) (5) (6) (7) .
Abbreviations: LDL, low density lipoproteins; FH, familial hypercholesterolemia; CHL, familial combined hyperlipidemia; FC serum, fetal calf serum; LPD serum, lipoprotein-deficient serum.
We have previously reported that fibroblasts obtained from five patients who exhibit the typical clinical syndrome of homozygous familial hypercholesterolemia (FH) neither bind LDL at the receptor site nor manifest any of the functions of the LDL receptor, even when examined in the presence of LDL concentrations 500 times higher than those required to produce maximal biologic effects in normal fibroblasts (1) (2) (3) (4) (5) (6) (7) . Thus, the receptor defect in these homozygotes' cells appeared to be due not to a reduced binding affinity for LDL but rather to an absence of functional receptor molecules (1-3). Cells from 10 typical FH heterozygotes, including six of the parents of the homozygous patients, were shown to contain about half the normal number of LDL receptor molecules on their surface (3, 8) . However, since the binding affinity for LDL was normal, the only detectable functional LDL receptor in the heterozygotes' cells represents the product of the single normal allele (3, 8) .
In this and in previous publications, we-use the term FH homozygote in a phenotypic sense to denote a distinct clinical syndrome characterized by the following three features: i, marked hypercholesterolemia, i.e., serum cholesterol levels greater than 600 mg/dl, ii, the childhood onset of cutaneous planar xanthomas that are especially prominent in the interdigital webs, and iii, premature coronary vascular disease (9-11). As clearly shown by the genetic studies of Khachadurian, this phenotype results when an individual inherits two mutant FH alleles-one from his heterozygous mother and the other from his heterozygous father (9, 12 (3) (4) (5) . Each of the three unrelated receptor-defective FH homozygotes meets the clinical and genetic criteria for diagnosis of a FH homozygote, as outlined above. A more detailed report of the clinical and genetic findings in these receptor-defective FH homozygotes and in their heterozygous parents is being prepared in collaboration with their physicians, Dr. Robert Lees of Boston and Dr. John P. Kane of San Francisco.
Cells. Skin biopsies were obtained with informed consent, and all fibroblast cultures were established in our laboratory. Biopsy specimens were obtained from the deltoid region in all patients listed in Table 1 All cells were grown in monolayer and used between the 5th and 20th passage. Cell lines were maintained in a humidified incubator (5% C02) at 370 in 75 cm2 stock flasks (Falcon) containing 10 ml of growth medium consisting of Eagle's minimum essential medium (Gibco, Cat. no. F-l) ,supplemented with penicillin (100 units/ml); streptomycin (100 Ag/ml); 20 mM Tricine-Cl (pH 7.4); 24 mM NaHCO3; 1% (v/v) nonessential amino acids; and 10% (v/v) fetal calf serum (Flow Laboratories). All experiments were done in a similar format: confluent monolayers of cells from stock flasks were dissociated with 0.05% trypsin-0.05%0 EDTA solution and were seeded (day 0) at a concentration of 1 X 105 cells per dish into 60 X 15 mm dishes (Falcon) containing 3 ml of growth medium with 10% fetal calf serum (FC serum).
On day 3 the medium was replaced with 3 ml of fresh growth medium containing 10% FC serum. On either day 4 or day 6, when the cells were not yet confluent, each monolayer was washed with 2 ml of Dulbecco's phosphate-buffered saline, and 2 ml of fresh medium containing 5% (v/v) lipoproteindeficient human serum (LPD serum) was added (final protein concentration, 2.5 mg/ml). All experiments were initiated either on day 5 or day 7 after the cells had been incubated for 24 hr in the presence of LPD serum.
Lipoprotein. Human LDL (density 1.019-1.063 g/ml) and LPD serum (density > 1.215 g/ml) were obtained from the plasma of healthy subjects and prepared by differential ultracentrifugation (7) . The concentration of the LDL preparations is expressed in terms of its protein content, which averaged 60% of the cholesterol concentration.
Assays. Hydroxymethylglutaryl-CoA reductase activity was measured in extracts of detergent-solubilized cells (7) . determined by thin-layer chromatography (5) .
Binding of 1265-labeled LDL to intact cell monolayers was determined as described (2) and the l2JI-labeled LDL (specific activity, 69 cpm/ng of protein) was prepared by a modification (15) of the method of MacFarlane (16) .
All values are expressed in terms of the cellular protein content as measured by the method of Lowry et al. (17) . Fig. 2A .
Whereas at 6 hr the normal cells reached a maximal response at an LDL concentration between 100 and 200 ,ug of protein per ml, the receptor-defective FH homozygotes showed a low rate of esterification that continued to increase as the concentration of LDL was raised up to at least 400 ,ug of protein per ml ( Fig. 2A, inset) . In contrast, the five previously described receptor-negative homozygotes (3, 5) normal subject and two homozygotes with familial hypercholesterolemia. Cell monolayers were grown as described in Methods. On day 7, after the cells had been incubated for 24 hr in medium containing LPD serum, 125I-labeled LDL (69 cpm/ng of protein) was added to give the indicated final concentration. After a further incubation for 6 hr at 370, cell monolayers were washed extensively and the total amount of 125I bound to the cells was determined as previously described (2) . Initials refer to the cell lines described in Table 1 . Normal (0); receptor-native FH homozygote (U); and receptor-defective FH homozygote (a).
cells reflected a defect in their LDL receptors, we compared 125I-labeled LDL binding in cells from one of these patients, one receptor-negative FH homozygote, and one normal subject (Fig. 3) . Consistent with previous findings, the normal cells (D.S.) took up '25I-labeled LDL by two processes (2) . One reached saturation at an LDL concentration of about 100 Ag of protein per ml; this represented high affinity binding to the LDL receptor. The second was nonsaturable and appeared to represent a nonspecific endocytosis of LDL (2) . As reported (1-3) and as shown in Fig. 3 , the high affinity component of LDL binding was absent in cells from the receptor-negative FH homozygotes (as in J.P.), and the only binding process observed in their cells was a nonsaturable component identical with the nonspecific component of the normal cells. From the data of Fig. 2 , it can be calculated that in the receptordefective cells the degree of stimulation of esterification and suppression of hydroxymethylglutaryl CoA reductase activity that was observed would have occurred if the binding were only about 10% of normal, which is too low to be reliably detected by the present 1251-labeled LDL binding assay. Thus, although at each LDL concentration, binding in the receptor-defective homozygote's cells (K.M.) was slightly and consistently higher than in the receptor-negative homozygote's cells (J.P.), the presence of a normal nonspecific component in these receptor-defective cells prevented a clear-cut demonstration of the defective receptor sites that are presumed to be present. This lack of detectable specific binding sites in these mutant cells does, however, serve to distinguish them from FH heterozygotes in whom the half normal number of receptors can easily be demonstrated (3) .
The sensitivity of the measurement of LDIstimulated cholesterol esterification permitted the development of a standardized assay that could distinguish between fibroblasts from patients in the various genetic groups. Several important variables had to be standardized so that the widest range of discrimination could be obtained. First 
